Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Clin Cancer Res (2024) 30 (5): 1022–1037.

https://doi.org/10.1158/1078-0432.CCR-23-2187

Published: 01 March 2024

View articletitled, Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Includes: Supplementary data

Journal Articles

Preclinical Development of [²¹¹At]meta- astatobenzylguanidine ([²¹¹At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

Vandana Batra, Minu Samanta, Mehran Makvandi, David Groff, Paul Martorano, Jimmy Elias, Pietro Ranieri, Matthew Tsang, Catherine Hou, Yimei Li, Bruce Pawel, Daniel Martinez, Ganesan Vaidyanathan, Sean Carlin, Daniel A. Pryma, John M. Maris

Clin Cancer Res (2022) 28 (18): 4146–4157.

https://doi.org/10.1158/1078-0432.CCR-22-0400

Published: 15 September 2022

View articletitled, Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

Includes: Supplementary data

Journal Articles

Abstract A009: Proteogenomic prioritization of immunotherapeutic targets in rhabdomyosarcoma nominate MEGF10 for preclinical development

Rawan Shraim, Amber K. Weiner, Karina L. Conkrite, Alexander B. Radaoui, John M. Maris, Yael P. Mosse, Sharon J. Diskin, Ahmet Sacan, Benjamin A. Garcia, Peter J. Houghton, Raushan T. Kurmasheva, Poul Sorensen, Gregg B. Morin, Brian Mooney

Clin Cancer Res (2022) 28 (18_Supplement): A009.

https://doi.org/10.1158/1557-3265.SARCOMAS22-A009

Published: 15 September 2022

View articletitled, Abstract A009: Proteogenomic prioritization of immunotherapeutic targets in rhabdomyosarcoma nominate MEGF10 for preclinical development

Journal Articles

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Clin Cancer Res (2021) 27 (10): 2938–2946.

https://doi.org/10.1158/1078-0432.CCR-20-4221

Published: 15 May 2021

View articletitled, The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Includes: Supplementary data

Journal Articles

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, Malcolm Smith, Barry L. Shulkin, Marguerite Parisi, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Julie R. Park, Paul M. Sondel

Clin Cancer Res (2021) 27 (8): 2179–2189.

https://doi.org/10.1158/1078-0432.CCR-20-3909

Published: 15 April 2021

View articletitled, Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Includes: Supplementary data

Journal Articles

Abstract PO-049: SARS-CoV-2 multiepitope vaccine constructs designed to drive long-term immunity in the majority of the population

Mark Yarmarkovich, John M. Warrington, Alvin Farrel, John M. Maris

Clin Cancer Res (2020) 26 (18_Supplement): PO-049.

https://doi.org/10.1158/1557-3265.COVID-19-PO-049

Published: 15 September 2020

View articletitled, Abstract PO-049: SARS-CoV-2 multiepitope vaccine constructs designed to drive long-term immunity in the majority of the population

Journal Articles

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Kristina A. Cole, Sharmistha Pal, Rachel A. Kudgus, Heba Ijaz, Xiaowei Liu, Charles G. Minard, Bruce R. Pawel, John M. Maris, Daphne A. Haas-Kogan, Stephan D. Voss, Stacey L. Berg, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel

Clin Cancer Res (2020) 26 (6): 1213–1219.

https://doi.org/10.1158/1078-0432.CCR-19-3470

Published: 13 March 2020

View articletitled, Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Includes: Supplementary data

Journal Articles

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study

Suzanne Shusterman, Arlene Naranjo, Collin Van Ryn, Jaquelyn A. Hank, Marguerite T. Parisi, Barry L. Shulkin, Sabah Servaes, Wendy B. London, Hiroyuki Shimada, Jacek Gan, Steven D. Gillies, John M. Maris, Julie R. Park, Paul M. Sondel

Clin Cancer Res (2019) 25 (20): 6044–6051.

https://doi.org/10.1158/1078-0432.CCR-19-0798

Published: 15 October 2019

View articletitled, Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study

Journal Articles

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Clin Cancer Res (2019) 25 (8): 2560–2574.

https://doi.org/10.1158/1078-0432.CCR-18-0432

Published: 15 April 2019

View articletitled, CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Includes: Supplementary data

Journal Articles

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Clin Cancer Res (2019) 25 (7): 2278–2289.

https://doi.org/10.1158/1078-0432.CCR-18-2728

Published: 01 April 2019

View articletitled, Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Includes: Supplementary data

Journal Articles

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Clin Cancer Res (2018) 24 (24): 6142–6149.

https://doi.org/10.1158/1078-0432.CCR-18-1381

Published: 13 December 2018

View articletitled, Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Includes: Supplementary data

Journal Articles

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma

Jun S. Wei, Igor B. Kuznetsov, Shile Zhang, Young K. Song, Shahab Asgharzadeh, Sivasish Sindiri, Xinyu Wen, Rajesh Patidar, Sushma Najaraj, Ashley Walton, Jaime M. Guidry Auvil, Daniela S. Gerhard, Aysen Yuksel, Daniel Catchpoole, Stephen M. Hewitt, Paul M. Sondel, Robert Seeger, John M. Maris, Javed Khan

Clin Cancer Res (2018) 24 (22): 5673–5684.

https://doi.org/10.1158/1078-0432.CCR-18-0599

Published: 15 November 2018

View articletitled, Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma

Includes: Supplementary data

Journal Articles

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Clin Cancer Res (2018) 24 (1): 189–196.

https://doi.org/10.1158/1078-0432.CCR-17-1767

Published: 02 January 2018

View articletitled, Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Includes: Supplementary data

Journal Articles

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

Clin Cancer Res (2017) 23 (7): 1785–1796.

https://doi.org/10.1158/1078-0432.CCR-16-1131

Published: 02 April 2017

View articletitled, Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

Includes: Supplementary data

Journal Articles

Identifying Rare Events in Rare Diseases

Edward F. Attiyeh, John M. Maris

Clin Cancer Res (2015) 21 (8): 1782–1785.

https://doi.org/10.1158/1078-0432.CCR-14-2314

Published: 14 April 2015

View articletitled, Identifying Rare Events in Rare Diseases

Journal Articles

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Gorlick, Hernan Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton

Clin Cancer Res (2015) 21 (4): 819–832.

https://doi.org/10.1158/1078-0432.CCR-14-2572

Published: 16 February 2015

View articletitled, Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Includes: Supplementary data

Journal Articles

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

JulieAnn Rader, Mike R. Russell, Lori S. Hart, Michael S. Nakazawa, Lili T. Belcastro, Daniel Martinez, Yimei Li, Erica L. Carpenter, Edward F. Attiyeh, Sharon J. Diskin, Sunkyu Kim, Sudha Parasuraman, Giordano Caponigro, Robert W. Schnepp, Andrew C. Wood, Bruce Pawel, Kristina A. Cole, John M. Maris

Clin Cancer Res (2013) 19 (22): 6173–6182.

https://doi.org/10.1158/1078-0432.CCR-13-1675

Published: 14 November 2013

View articletitled, Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Includes: Supplementary data

Journal Articles

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Yael P. Mossé, Emily Lipsitz, Elizabeth Fox, David T. Teachey, John M. Maris, Brenda Weigel, Peter C. Adamson, Mark A. Ingle, Charlotte H. Ahern, Susan M. Blaney

Clin Cancer Res (2012) 18 (21): 6058–6064.

https://doi.org/10.1158/1078-0432.CCR-11-3251

Published: 06 November 2012

View articletitled, Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Journal Articles

New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome

Kristina A. Cole, John M. Maris

Clin Cancer Res (2012) 18 (9): 2423–2428.

https://doi.org/10.1158/1078-0432.CCR-11-1409

Published: 30 April 2012

View articletitled, New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome

Journal Articles

Phase I Study of Vincristine, Irinotecan, and ¹³¹I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Steven G. DuBois, Louis Chesler, Susan Groshen, Randall Hawkins, Fariba Goodarzian, Hiroyuki Shimada, Greg Yanik, Michael Tagen, Clinton Stewart, Yael P. Mosse, John M. Maris, Denice Tsao-Wei, Araz Marachelian, Judith G. Villablanca, Katherine K. Matthay

Clin Cancer Res (2012) 18 (9): 2679–2686.

https://doi.org/10.1158/1078-0432.CCR-11-3201

Published: 30 April 2012

View articletitled, Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Preclinical Development of [²¹¹At]meta- astatobenzylguanidine ([²¹¹At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

Abstract A009: Proteogenomic prioritization of immunotherapeutic targets in rhabdomyosarcoma nominate MEGF10 for preclinical development

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Abstract PO-049: SARS-CoV-2 multiepitope vaccine constructs designed to drive long-term immunity in the majority of the population

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

Identifying Rare Events in Rare Diseases

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome

Phase I Study of Vincristine, Irinotecan, and ¹³¹I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only